|
Gene: SELENOO |
Gene summary for SELENOO |
Gene summary. |
Gene information | Species | Human | Gene symbol | SELENOO | Gene ID | 83642 |
Gene name | selenoprotein O | |
Gene Alias | SELO | |
Cytomap | 22q13.33 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9BVL4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83642 | SELENOO | NAFLD1 | Human | Liver | NAFLD | 8.77e-12 | 8.30e-01 | -0.04 |
83642 | SELENOO | S43 | Human | Liver | Cirrhotic | 1.90e-03 | -1.16e-01 | -0.0187 |
83642 | SELENOO | HCC1_Meng | Human | Liver | HCC | 1.07e-06 | -1.56e-01 | 0.0246 |
83642 | SELENOO | HCC2_Meng | Human | Liver | HCC | 2.30e-06 | -1.56e-01 | 0.0107 |
83642 | SELENOO | cirrhotic1 | Human | Liver | Cirrhotic | 1.07e-06 | -1.56e-01 | 0.0202 |
83642 | SELENOO | cirrhotic2 | Human | Liver | Cirrhotic | 2.30e-06 | -1.56e-01 | 0.0201 |
83642 | SELENOO | cirrhotic3 | Human | Liver | Cirrhotic | 5.80e-03 | -1.56e-01 | 0.0215 |
83642 | SELENOO | HCC1 | Human | Liver | HCC | 8.34e-12 | 3.42e+00 | 0.5336 |
83642 | SELENOO | HCC2 | Human | Liver | HCC | 2.98e-07 | 3.61e+00 | 0.5341 |
83642 | SELENOO | Pt13.a | Human | Liver | HCC | 2.30e-06 | -1.56e-01 | 0.021 |
83642 | SELENOO | Pt13.b | Human | Liver | HCC | 3.53e-02 | -1.56e-01 | 0.0251 |
83642 | SELENOO | Pt14.d | Human | Liver | HCC | 1.07e-06 | -1.56e-01 | 0.0143 |
83642 | SELENOO | S014 | Human | Liver | HCC | 1.84e-07 | 4.17e-01 | 0.2254 |
83642 | SELENOO | S015 | Human | Liver | HCC | 5.15e-06 | 4.54e-01 | 0.2375 |
83642 | SELENOO | S016 | Human | Liver | HCC | 4.83e-06 | 3.80e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SELENOO | SNV | Missense_Mutation | rs1052832 | c.2006C>T | p.Ser669Leu | p.S669L | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | ||
SELENOO | SNV | Missense_Mutation | rs201408834 | c.658N>A | p.Val220Ile | p.V220I | protein_coding | tolerated(0.2) | benign(0.416) | TCGA-VQ-A8PB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR | |
SELENOO | SNV | Missense_Mutation | rs760796138 | c.1313N>T | p.Ala438Val | p.A438V | protein_coding | tolerated(0.29) | benign(0.037) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |